Notícias Verastem Inc - VSTM | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Verastem Inc (VSTM)
Verastem Inc (VSTM) Notícias

Verastem Inc (VSTM)

5,79

-0,30

(-4,93%)

Fechado 08 Fevereiro 6:00PM

Atrasado por 15 minutos

5,85

0,06

(1,04%)

Após o horário de negociação: 9:58PM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology to Participate in Upcoming Investor Conferences

1
2
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições